Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks - Seite 2

from pain treatment. As a leader in pain innovation and as an opioid
manufacturer, Grünenthal is highly committed to ensuring that its employees,
customers, patients and also its partners have a thorough understanding of the
company's stance on the responsible medical use of opioids in pain. The company
has fostered a mindset shift along the full value chain by ensuring that all
opioid-related materials contain Grünenthal's statement on responsible use of
opioids - clearly highlighting the risks and benefits of this class of
medicines. In addition, Grünenthal had established a dedicated standing
governance body to provide and promote clear guidance, coherent behavior,
continuous improvement, training and control mechanisms.

Ensure access to medicine Grünenthal is committed to ensuring the availability
of key medicines to address unmet medical needs in the markets we serve. In the
US, for instance, 5 million patients are in need of neuropathic pain treatment
associated with diabetes. With the US FDA label extension of one of our
non-opioid pain medicines for the treatment of neuropathic pain associated with
diabetic peripheral neuropathy of the feet, Grünenthal has ensured patients get
access to this much needed treatment. At the same time, the company is focused
on addressing unmet therapeutic needs in underserved markets by offering
specialized non-opioid pain medicines.

Innovate pain management Grünenthal's research and development strategy focuses
on tackling in pain and collaborating with partners to address the huge unmet
needs in pain. Through biennial grants of EUR200,000 provided by Grünenthal and
the EFIC, the company supports young scientists early in their career in
carrying out innovative clinical pain research. Since foundation of the
EFIC-Grünenthal Grant in 2004, approximately EUR1.6 million was awarded to fund
65 projects. In addition, to drive patient-centric innovation in chronic pain
and neurological disorders and award patient-centric and scientifically robust
innovation, the company supports the Brain, Mind, and Pain Patient-Centered
Innovation Grant, which awards EUR90,000 biennially to research proposals to
encourage patient-centered innovation that leads to improvements in the life
conditions of pain patients.

Raise awareness for "pain as a disease" Chronic pain is an enormous global
health problem affecting around 10% of the world's population. Grünenthal raises
awareness about the impact of pain by supporting a multi-stakeholder platform,
called the Societal Impact of Pain platform, which fosters the development of
pain policies on national level. With Grünenthal's Pain Toolkit, the company has